Skyrizi

acquisition merger arrows

Biotech

AbbVie ends development of IL-1 asset in ulcerative colitis

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis after a phase 2 study revealed insufficient efficacy results.

Gabrielle Masson Jul 31, 2025 12:32pm

Fierce Pharma

AbbVie will continue to pursue external innovation for long-term

Jul 31, 2025 11:44am

skin cells epidermis layers lotion serum

Innovent looks to Chinese regulators after ph. 3 psoriasis win

May 28, 2024 7:55am

AbbVie

AbbVie coughs up nearly $50M for Cugene's autoimmune med

May 16, 2022 10:05am